Clinical study of levothyroxine sodium in the treatment of subclinical hypothyroidism during pregnancy / 中国基层医药

ABSTRACT

Objective:To investigate the effect of levothyroxine sodium tablets on homocysteine (Hcy), antithyroid peroxidase antibody (TPO-Ab), thyroid function, folic acid and vitamin B 12 levels and pregnancy outcome in patients with subclinical hypothyroidism (SCH) during pregnancy. Methods:From January 2018 to August 2019, 120 cases of pregnant SCH patients in Shaoxing Central Hospital were selected and divided into control group and observation group according to the random digital table method, with 60 cases in each group.The observation group was given levothyroxine sodium tablet intervention, while the control group was not given any drug intervention.The changes of Hcy, TPO-Ab, thyroid function, folate level and pregnancy outcome were compared before and after treatment.Results:The serum levels of Hcy[(7.79±0.64)μmol/L]and TPO-Ab[(26.59±2.76)U/L] in the observation group were lower than those in the control group[(8.49±0.87)μmol/L and (30.49±3.25)U/L]( t=5.020, 7.085, all P<0.05). The serum TSH level[(2.25±0.48) mIU /L] in the observation group was lower than that in the control group[(3.49±0.70)mIU/L]( t=11.317, P<0.05). The levels of folate[(12.17±1.08)μg/L]and vitamin B 12[(487.23±26.23)ng/L] in the observation group were lower than those in the control group[(10.80±1.29)μg/L and (442.81±31.56)ng/L]( t=6.308, 8.385, all P<0.05). The incidence of adverse pregnancy outcome in the observation group (10.00%) was lower than that in the control group (28.33%) (χ 2=6.508, P<0.05). Conclusion:Levothyroxine sodium tablets can reduce Hcy and TPO-Ab levels, increase TSH, folate and vitamin B 12 levels, and reduce adverse pregnancy outcomes.